Navigation Links
Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen
Date:7/23/2014

ated that 2/3 of all MPS II patients will be affected with CNS disease; this translates into a prevalence of around 1,200 patients worldwide.  

NOTES TO EDITORS

Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We focus on providing treatments in Neuroscience, Rare Diseases, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas.

http://www.shire.com

FORWARD - LOOKING STATEMENTS - "SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included in this announcement that are not historical facts are forward-looking statements. Forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, that:

• Shire's products may not be a commercial success;

• revenues from ADDERALL XR are subject to generic erosion and revenues from INTUNIV will become subject to generic competition starting in December 2014;

• the failure to obtain and maintain reimbursement, or an adequate level of reimbursement, by third-party payors in a timely manner for Shire's products may impact future revenues, financial condition and results of operations;

• Shire conducts its own manufacturing operations for certain of its Rare Diseases products and is reliant on third party contractors to manufacture other products and to provide goods and services. Some of Shire's products or ingredients are only available from a single approved sourc
'/>"/>

SOURCE Shire plc
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
2. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
3. Shire plc: First Quarter 2012 Results Date Notification - April 26, 2012
4. Shire Facebook Page Increases Awareness of Hereditary Angioedema (HAE) in Support of First HAE Awareness Day May 16th
5. Berkshire Corporation Offers Live Chat For Americas Website and Shopping Cart
6. Shire Changes its NASDAQ Ticker Symbol to SHPG
7. Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
8. Shire and Boston Childrens Hospital Enter Into Broad Research Collaboration
9. Shire Reaches Agreement in Principle With U.S. Government
10. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
11. Shire to Acquire SARcode Bioscience, Expands Presence in Ophthalmology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... 25, 2015 Accelovance, a therapeutically focused contract ... "Best Contract Research Organization" at the upcoming Vaccine Industry ... This is the eighth consecutive year ... award, winning for "Best Contract Research Organization" in 2009, ... in 2013. "We,re excited to be a ...
(Date:3/25/2015)... (PRWEB) March 25, 2015 An increase ... ingredients in all forms of food nutrients, regulatory changes ... a substantial rise in demand for natural astaxanthin over ... started to ramp up their capacities to satisfy the ... natural and synthetic source astaxanthin (used in nutraceuticals, aqua ...
(Date:3/25/2015)... Francisco, CA (PRWEB) March 25, 2015 ... Support for Novel Mechanism of Action in Neuromuscular ... 25, 2015 – Cytokinetics, Incorporated (Nasdaq: CYTK) announced ... fast skeletal muscle troponin activator tirasemtiv in the ... a Phase IIa “Evidence of Effect” or hypothesis-generating ...
(Date:3/25/2015)... Researchers at Ancon Medical Inc. have ... enable broader and less invasive screening for cancer, ... breath screen. The Minnesota-based medical device maker will ... Administration (FDA) approval process and is targeting a ... Tagging device. , Ancon Medicals nanoparticle breakthrough comes ...
Breaking Biology Technology:Accelovance Nominated for 2015 Vaccine Industry Excellence (ViE) Awards 2Global Astaxanthin Market to Reach Value of USD 1.1 billion by 2020, Expects Industry Experts in New Report Available at MarketPublishers.com 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 3Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 4Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 5Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 6Ancon Medical Researchers Make Nanotechnology Breakthrough for Disease Screening Technology 2Ancon Medical Researchers Make Nanotechnology Breakthrough for Disease Screening Technology 3
... LLC (the "Purchaser"), a wholly owned subsidiary of Biotechnology Value ... cash tender offer to purchase any and all of the ... ) ("Avigen") that BVF does not own at a price ... offer price represents a 35% premium over Avigen,s closing stock ...
... CEDAR KNOLLS, N.J., Jan. 22 ScienceFirst ... associates have joined the Cedar Knolls office.(Photo: ... http://www.newscom.com/cgi-bin/prnh/20090122/NY61733-b )Valery Sudakin, PhD, has been ... Sudakin was an investigator at GlaxoSmithKline, where ...
... Jan. 22 MichBio, the association for,Michigan,s biosciences ... compiling,the 2009 Michigan Biosciences Directory and Resource Guide, ... biosciences companies and,organizations. The directory will be included ... bi-annual publication spotlighting Michigan,biosciences news and trends. , ...
Cached Biology Technology:BVF Acquisition LLC, a Wholly-Owned Subsidiary of Biotechnology Value Fund, L.P., Commences Tender Offer for Any and All Outstanding Shares of Avigen at $1.00 Per Share 2BVF Acquisition LLC, a Wholly-Owned Subsidiary of Biotechnology Value Fund, L.P., Commences Tender Offer for Any and All Outstanding Shares of Avigen at $1.00 Per Share 3ScienceFirst Staff Expansion 2MichBio Will Publish 2009 Michigan Biosciences Directory and Resource Guide 2
(Date:3/24/2015)... Mar. 24, 2015 Research and Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ... Biometrics - Global Strategic Business Report" report to their offering. ... Voice Biometrics in US$ Thousands by the following Segments: Face Biometrics, ... US, Canada , Japan , ... Middle East & Africa , ...
(Date:3/24/2015)... Fla. , March 24, 2015   ... management solutions, today announced that its U.are.U ® ... accessory retailer Goorin Bros . to achieve ... biometrics-based solution secures access to the POS terminal, ... increased risk of data breaches. ...
(Date:3/23/2015)... , March 23, 2015   HOYOS Labs ... management company, today announced that the Company will demonstrate ... both enterprise and consumers at Connect:ID on March 23 ... HOYOS Labs will highlight the IEEE Biometric Open ... ; and enterprise access control system. BOPS was ...
Breaking Biology News(10 mins):Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3
... cell factor overexpressed both in brain tumor cells and ... inducing angiogenesis. The research study, published in the April ... cells and surrounding tissues and may have substantial significance ... the most lethal types of tumor, malignant gliomas. ...
... play an important role in regulating blood flow in ... assumptions underlying today's most sophisticated brain imaging techniques and ... understanding Alzheimer's disease. , In a paper to appear ... available on-line, scientists at the University of Rochester Medical ...
... the Virginia Bioinformatics Institute at Virginia Tech have ... range of microbial genome sequences. , The VBI ... recent article published in Nucleic Acids Research (Vol.34, ... the plant pathogens Phytophthora sojae and Phytophthora ramorum. ...
Cached Biology News:Growth factor-promoting angiogenesis expressed in tumor cells and normal neurons 2Blood flow in brain takes a twist, affecting views of Alzheimer's 2Blood flow in brain takes a twist, affecting views of Alzheimer's 3Virginia Bioinformatics Institutes launches microbial database 2
dynactin 4, mRNA (cDNA clone MGC:3248 IMAGE:3505855), complete cds...
Edited by D. Rickwood, T.C. Ford and J.T. Steensgaard (1994) Compiles core data required by researchers carrying out any centrifugal separation, whether working with cells, organelles or macromolec...
MSE ANTI CAN. CD3:FITC/RAT ANTI CD4:RPE...
Because it is manufactured at our ISO 9001–certified facilities in Eugene, Oregon, we can guarantee that FluoroPure Grade DAPI is greater than or equal to 98% pure by HPLC....
Biology Products: